A Randomised, Controlled Study Investigating the Safety and Anticoagulant Activity of Administration of Low-molecular-weight Heparin in Healthy Male Subjects Treated With the Monoclonal Anti-factor VIII Antibody, TB-402 and the Safety and Anticoagulant Activity of Administration of TB-402 in Healthy Male Subjects Treated With Warfarin
Phase of Trial: Phase I
Latest Information Update: 10 Sep 2018
At a glance
- Drugs TB 402 (Primary) ; Low molecular weight heparins; Warfarin
- Indications Thrombosis
- Focus Pharmacodynamics
- Sponsors Oxurion; ThromboGenics
- 13 May 2008 Top-line results are expected by mid 2008 according to a ThromboGenics media release.
- 25 Feb 2008 New trial record.